Exosomes in Inflammatory Bowel Disease: What We Learnt So Far?

Exosomes in Inflammatory Bowel Disease: What We Learnt So Far? Curr Drug Targets. 2020 Apr 27;: Authors: Wang H, Ye C, Wu Y, Yang P, Chen C, Liu Z, Wang X Abstract Inflammatory bowel disease (IBD) is an immune-mediated chronic inflammatory disease. Although the uncertain etiology, there is marked dysbalanced of mucosal immune responses in part shaped with genetic susceptibility and intestinal microbial dysbiosis. To suppress inflammatory activity adequately and maintain it are the main goals for current therapies. However, corticosteroids are only suitable for therapy of active disease, and the effects of immunosuppressive agents are mainly limited to maintenance of remission. Biologics have become widely available, which provide therapeutic benefits to the IBD patients. But only part of patients benefit from them. Thus, there is an urge for the development of new substances in the therapy of IBD. Exosomes are nano-sized lipid vesicles identified recently. They be secreted from all living cells, and then distribute in various human body fluids. The components, such as microRNAs and functional proteins, secreted by exosomes in different cells have been reported to involve in pathogenesis of IBD. Therefore, exosomes have the potential to become the appealing particles in treating IBD as a cell-free therapeutic approach, and the biomarkers for diagnosis and monitoring disease status. Researches are further needed to investigate the prac...
Source: Current Drug Targets - Category: Drugs & Pharmacology Authors: Tags: Curr Drug Targets Source Type: research